Key Takeaways DHR posted Q2 adjusted EPS of $1.80 and sales of$5.94B, topping consensus and rising year over year. Life Sciences lagged in core sales and swung to a loss, while Biotechnology led with 6% core sales growth. DHR raised its 2025 adjusted EPS forecast to $7.70-$7.80, up from the prior $7.60-$7.75 range.Danaher Corporation’s (DHR) second-quarter 2025 adjusted earnings of $1.80 per share beat the Zacks Consensus Estimate of$1.64. The bottom line increased 4.7% year over year.Danaher reported n ...